Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis.
D000596:Amino Acids / Q000378:metabolism; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001381:Azepines / Q000627:therapeutic use*; D001835:Body Weight; D061945:Caspase Inhibitors; D003094:Collagen / Q000032:analysis; D004195:Disease Models, Animal; D004435:Eating; D005260:Female; D006614:Hindlimb; D007546:Isoquinolines / Q000627:therapeutic use*; D007596:Joints / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008815:Mice, Inbred Strains; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011724:Pyridazines / Q000627:therapeutic use*
D000596:Amino Acids; D000893:Anti-Inflammatory Agents; D001381:Azepines; D061945:Caspase Inhibitors; D007546:Isoquinolines; D011724:Pyridazines; C015484:pyridinoline; D003094:Collagen; C476331:pralnacasan